Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 36

Related Articles by Review for PubMed (Select 22192883)

1.

Targeting the S and G2 checkpoint to treat cancer.

Chen T, Stephens PA, Middleton FK, Curtin NJ.

Drug Discov Today. 2012 Mar;17(5-6):194-202. doi: 10.1016/j.drudis.2011.12.009. Epub 2011 Dec 15. Review.

PMID:
22192883
2.

G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer.

Bucher N, Britten CD.

Br J Cancer. 2008 Feb 12;98(3):523-8. doi: 10.1038/sj.bjc.6604208. Epub 2008 Jan 29. Review.

3.

Inhibitors of the G2 DNA damage checkpoint and their potential for cancer therapy.

Anderson HJ, Andersen RJ, Roberge M.

Prog Cell Cycle Res. 2003;5:423-30. Review.

PMID:
14593736
4.
5.

Chk1 inhibitors for novel cancer treatment.

Tao ZF, Lin NH.

Anticancer Agents Med Chem. 2006 Jul;6(4):377-88. Review.

PMID:
16842237
6.

G2 checkpoint abrogators as anticancer drugs.

Kawabe T.

Mol Cancer Ther. 2004 Apr;3(4):513-9. Review.

7.

DNA damage checkpoints: implications for cancer therapy.

O'Connor PM, Fan S.

Prog Cell Cycle Res. 1996;2:165-73. Review.

PMID:
9552393
8.

Unleashing Chk1 in cancer therapy.

Carrassa L, Damia G.

Cell Cycle. 2011 Jul 1;10(13):2121-8. Epub 2011 Jul 1. Review.

9.

Checkpoint kinase inhibitors: a patent review (2009 - 2010).

Lainchbury M, Collins I.

Expert Opin Ther Pat. 2011 Aug;21(8):1191-210. doi: 10.1517/13543776.2011.586632. Epub 2011 May 20. Review.

PMID:
21599421
10.

[Cell cycle regulation after exposure to ionizing radiation].

Teyssier F, Bay JO, Dionet C, Verrelle P.

Bull Cancer. 1999 Apr;86(4):345-57. Review. French.

PMID:
10341340
11.

DNA damage detection and repair pathways--recent advances with inhibitors of checkpoint kinases in cancer therapy.

Ashwell S, Zabludoff S.

Clin Cancer Res. 2008 Jul 1;14(13):4032-7. doi: 10.1158/1078-0432.CCR-07-5138. Review.

12.

Novel checkpoint 1 inhibitors.

Prudhomme M.

Recent Pat Anticancer Drug Discov. 2006 Jan;1(1):55-68. Review.

PMID:
18221026
13.

Chemical strategies for development of ATR inhibitors.

Llona-Minguez S, Höglund A, Jacques SA, Koolmeister T, Helleday T.

Expert Rev Mol Med. 2014 May 9;16:e10. doi: 10.1017/erm.2014.10. Review.

PMID:
24810715
14.

The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design.

Thompson R, Eastman A.

Br J Clin Pharmacol. 2013 Sep;76(3):358-69. doi: 10.1111/bcp.12139. Review.

15.

Potentiation of DNA-damage-induced cytotoxicity by G2 checkpoint abrogators.

Tenzer A, Pruschy M.

Curr Med Chem Anticancer Agents. 2003 Jan;3(1):35-46. Review.

PMID:
12678913
16.

Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics.

Ma CX, Janetka JW, Piwnica-Worms H.

Trends Mol Med. 2011 Feb;17(2):88-96. doi: 10.1016/j.molmed.2010.10.009. Epub 2010 Nov 17. Review.

PMID:
21087899
17.

The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.

Smith J, Tho LM, Xu N, Gillespie DA.

Adv Cancer Res. 2010;108:73-112. doi: 10.1016/B978-0-12-380888-2.00003-0. Review.

PMID:
21034966
18.
19.

Combining DNA damaging agents and checkpoint 1 inhibitors.

Prudhomme M.

Curr Med Chem Anticancer Agents. 2004 Sep;4(5):435-8. Review.

PMID:
15379699
20.

Anticancer therapy with checkpoint inhibitors: what, where and when?

Garrett MD, Collins I.

Trends Pharmacol Sci. 2011 May;32(5):308-16. doi: 10.1016/j.tips.2011.02.014. Epub 2011 Mar 30. Review.

PMID:
21458083
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk